Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases.

Current Opinion in Rheumatology
Milena GianfrancescoPhilip C Robinson

Abstract

The novel coronavirus 2019 (COVID-19) pandemic is of special concern for patients with immune-mediated inflammatory disease (IMID) and those who care for them because of the potential for worse outcomes. This article analyzes peer-reviewed research on the epidemiology and outcomes of COVID-19 in those with IMID. Published literature on approximately 1400 patients was included from rheumatology, gastroenterology, and dermatology. Data suggest that those who are older and have comorbidities have poorer outcomes. This is consistent with the reports from the general population of patients with COVID-19. Adjusted analyses from the largest published studies demonstrate independent effects of systemic glucocorticoids, as well as age and comorbidities with poorer COVID-19 outcomes (SECURE-IBD registry, n = 525; COVID-19 Global Rheumatology Alliance registry, n = 600); biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe outcomes. These early results will require validation in population-based studies as more data becomes available. Current data suggest that similar to the general population, age, and comorbidities are risk factors for poorer COVID-19 outcomes in patients w...Continue Reading

References

Feb 29, 2020·The New England Journal of Medicine·Wei-Jie GuanUNKNOWN China Medical Treatment Expert Group for Covid-19
Apr 4, 2020·Nature Reviews. Rheumatology·Philip C Robinson, Jinoos Yazdany
Apr 7, 2020·JAMA : the Journal of the American Medical Association·Giacomo GrasselliUNKNOWN COVID-19 Lombardy ICU Network
Apr 23, 2020·JAMA : the Journal of the American Medical Association·Safiya RichardsonTheodoros P Zanos
Apr 30, 2020·The New England Journal of Medicine·Rebecca HabermanJose U Scher
May 4, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Mariangela AlloccaLaurent Peyrin-Biroulet
May 10, 2020·Arthritis Care & Research·Emily SirotichUNKNOWN COVID-19 Global Rheumatology Alliance Steering Committee
May 24, 2020·Annals of the Rheumatic Diseases·Cong YeLingli Dong

❮ Previous
Next ❯

Citations

Oct 15, 2020·Annals of the Rheumatic Diseases·Shintaro AkiyamaAtsushi Sakuraba
Nov 5, 2020·Expert Review of Clinical Immunology·Isabelle AmiguesMaximilian Konig
Dec 22, 2020·Frontiers in Pediatrics·Adrien SchvartzIsabelle Kone-Paut
Jan 5, 2021·Current Opinion in Rheumatology·Philip C RobinsonPedro M Machado
Nov 5, 2020·Arthritis & Rheumatology·Milena A GianfrancescoUNKNOWN COVID-19 Global Rheumatology Alliance
Jan 21, 2021·Best Practice & Research. Clinical Rheumatology·Rebecca GraingerPhilip C Robinson
Mar 3, 2021·Best Practice & Research. Clinical Rheumatology·Tiffany TaylorMilena A Gianfrancesco
Mar 4, 2021·The Lancet Rheumatology·Leonard H CalabreseJolan E Walter
Sep 7, 2020·Journal of the American Academy of Dermatology·Joel M GelfandChristopher T Ritchlin
May 19, 2021·Zeitschrift für Rheumatologie·Ellen KuhlmannAlexandra Jablonka
Jun 13, 2021·Journal for Immunotherapy of Cancer·Jason D GoldmanPer Ljungman
Aug 17, 2021·Current Opinion in Rheumatology·Sebastian E SattuiIris Navarro-Millán

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.